Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SL Science HoldingSLBT +24.39%12 Debt-to-EBITDA is -0.05 as of Dec. 2025. GuruFocus rates SLBT with a GF Score™ of 12/100. The stock has 3 warning signs investors should review. Among 296 Biotechnology companies, SL Science Holding ranks worse than 337837.5% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for SL Science Holding's Debt-to-EBITDA or its related term are showing as below:
SLBT'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.06 Med: 2.02 Max: 4.1
Current: -0.06
During the past 3 years, the highest Debt-to-EBITDA Ratio of SL Science Holding was 4.10. The lowest was -0.06. And the median was 2.02.
SLBT's Debt-to-EBITDA is ranked worse than 100% of 296
companies
in the Biotechnology industry
Industry Median: 1.185
vs SLBT: -0.06
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
SL Science Holding Debt-to-EBITDA Related Terms
SL Science Holding Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for SL Science Holding's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SL Science Holding Debt-to-EBITDA Chart
SL Science Holding Annual Data
Trend
Dec23
Dec24
Dec25
Debt-to-EBITDA
4.10
0.00
-0.06
SL Science Holding Semi-Annual Data
Dec23
Jun24
Dec24
Jun25
Dec25
Debt-to-EBITDA
N/A
0.00
0.00
-0.10
-0.05
SLBT vs DMRA, BCAX, TYRA: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, SL Science Holding's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SL Science Holding Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SL Science Holding's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where SL Science Holding's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
SL Science Holding (SLBT) has a Debt-to-EBITDA of -0.05 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on SL Science Holding. According to the industry distribution chart, SL Science Holding ranks #999999 out of 296 companies in the Biotechnology industry.
Is SL Science Holding's Debt-to-EBITDA too high?
SL Science Holding's current Debt-to-EBITDA is -0.05. Based on the distribution chart, SL Science Holding ranks #999999 out of 296 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, SL Science Holding has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does SL Science Holding's Debt-to-EBITDA compare to DMRA and BCAX?
According to the Biotechnology industry distribution chart, SL Science Holding ranks #999999 out of 296 companies for Debt-to-EBITDA. This places SL Science Holding in the lower half of its industry. The industry median Debt-to-EBITDA is 1.19. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.19, based on 296 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on SL Science Holding. For the Biotechnology industry, the median Debt-to-EBITDA is 1.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SL Science Holding's current Debt-to-EBITDA is -0.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SL Science Holding stock overvalued right now?
SL Science Holding (SLBT) has a current Debt-to-EBITDA of -0.05. The current Debt-to-EBITDA is -0.05. SL Science Holding's overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For SL Science Holding (SLBT), the current Debt-to-EBITDA is -0.05 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
SL Science Holding Ltd is a biomedical company specialized in developing cellular and gene therapies advancing regenerative medicine and cancer treatment. It utilizes immune stem cells to target cancer and bovine-derived milk exosomes to regenerate damaged tissues, thus potentially offering expansive medical applications for its products. With proprietary technologies such as Armed-T and Gamma Delta T cells, as well as exosome applications in skincare and cancer recovery. It operates in three segments namely Exosome products, CD-19 Armed-T products, and GDT cell therapy products. It derives revenue from Exosome products segment.
12GF Score
Get the complete analysis for SLBT
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SLBT has been successfully added to your 
